NASDAQ: CLLSCellectis Sa Stock
$2.49-0.01 (-0.4%)
Updated Apr 25, 2024
CLLS Price
$2.49
Fair Value Price
N/A
Market Cap
$138.40M
52 Week Low
$0.96
52 Week High
$3.77
P/E
-1.51x
P/B
1.82x
P/S
3.6x
PEG
N/A
Dividend Yield
N/A
Revenue
$24.41M
Earnings
-$85.01M
Gross Margin
94.8%
Operating Margin
-178.86%
Profit Margin
-348.3%
Debt to Equity
1.76
Operating Cash Flow
-$66M
Beta
1.43
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CLLS Overview
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CLLS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CLLS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CLLS is good value based on its book value relative to its share price (1.82x), compared to the US Biotechnology industry average (5.8x)
P/B vs Industry Valuation
CLLS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CLLS due diligence checks available for Premium users.
Be the first to know about important CLLS news, forecast changes, insider trades & much more!
CLLS News
Valuation
CLLS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.51x
Industry
15.41x
Market
40.97x
CLLS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.82x
Industry
5.8x
CLLS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CLLS's financial health
Profit margin
Revenue
$1.6M
Net Income
-$17.5M
Profit Margin
-1,064%
CLLS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CLLS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$209.7M
Liabilities
$133.6M
Debt to equity
1.76
CLLS's short-term assets ($96.49M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CLLS's short-term assets ($96.49M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CLLS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CLLS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$17.1M
Investing
-$300.0k
Financing
$1.7M
CLLS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CLLS vs Biotech Stocks
Cellectis Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.